Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19247100 | CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODS | June 2025 | December 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18714111 | CONJUGATES, THEIR COMPOSITIONS, AND THEIR RELATED METHODS | May 2024 | April 2025 | Allow | 11 | 0 | 0 | Yes | No |
| 18649583 | METHOD FOR INHIBITING PROLIFERATION OF CANCER CELLS | April 2024 | April 2025 | Allow | 11 | 1 | 0 | No | No |
| 18649785 | METHOD FOR INHIBITING PROLIFERATION OF CANCER CELLS | April 2024 | May 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18248325 | HETEROARYL AMIDE INHIBITORS OF CD38 | April 2023 | August 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 18123102 | INTERMEDIATES FOR MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | March 2023 | August 2025 | Allow | 29 | 2 | 0 | Yes | No |
| 18172722 | SALTS OF A DIHYDROOROTATE DEHYDROGENASE (DHOD) INHIBITOR | February 2023 | March 2026 | Abandon | 37 | 2 | 0 | No | No |
| 17972818 | GLYCEROL ACETAL SULFATE AND SULFONATE SURFACTANTS | October 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17906014 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17908197 | Method for Producing Mono-Cross-Coupled Aromatic Compound Having Leaving Group | August 2022 | August 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17798784 | SPIROCYCLIC INHIBITORS OF HEPATITIS B VIRUS | August 2022 | May 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17929005 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | April 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 17859724 | MODIFIED ZINC OXIDE NANOCOMPOSITE, ANTIBIOTIC COMPOSITION COMPRISING THE SAME, AND COMBINATION PREPARATION WITH THE SAME | July 2022 | March 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 17850289 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | June 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17788346 | INDAZOLE COMPOUNDS | June 2022 | June 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 17845495 | METHODS OF PREPARING N6-((2-AZIDOETHOXY)CARBONYL)LYSINE | June 2022 | July 2025 | Allow | 37 | 0 | 0 | Yes | No |
| 17840563 | DOPAMINE D3 RECEPTOR LIGANDS FOR TREATMENT OF DYSKINESIA | June 2022 | June 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17756413 | POTENT AND SELECTIVE AZAINDOLE INHIBITORS OF CDK8 AND CDK19 | May 2022 | May 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17756011 | CHIRAL SYNTHESIS OF A TERTIARY ALCOHOL | May 2022 | May 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17771083 | Small Molecule Compound | April 2022 | September 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17766095 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | April 2022 | September 2025 | Abandon | 42 | 1 | 1 | No | No |
| 17765483 | LYOPHILIZED COMPOSITION COMPRISING (S)-ISOPROPYL 2-((S)-2-ACETAMIDO-3-(1H-INDOL-3-YL)PROPANAMIDO)-6-DIAZO-5-OXOHEXANOATE FOR INTRAVENOUS ADMINISTRATION AND THE USE THEREOF | March 2022 | December 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17761829 | PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULFUR AND SULFOXIMINE CONTAINING SUBSTITUENTS | March 2022 | August 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17760873 | SUBSTITUTED N-HETEROCYCLIC CARBOXAMIDES AS ACID CERAMIDASE INHIBITORS AND THEIR USE AS MEDICAMENTS | March 2022 | September 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17639183 | PERK INHIBITING IMIDAZOLOPYRAZINE COMPOUNDS | February 2022 | February 2025 | Allow | 35 | 0 | 0 | No | No |
| 17639110 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | February 2022 | July 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17633789 | 2-CYANOACRYLATE COMPOUND AND ADHESIVE COMPOSITION | February 2022 | September 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17632333 | KIF18A INHIBITORS | February 2022 | August 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17632334 | KIF18A INHIBITORS | February 2022 | September 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17630742 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF PARASITIC INFECTIONS | January 2022 | May 2025 | Allow | 39 | 1 | 0 | No | No |
| 17628195 | TRICYCLIC DERIVATIVES AS HYPOXIA INDUCIBLE FACTOR-2(ALPHA) INHIBITORS | January 2022 | June 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17279674 | NOVEL METHOD FOR PREPARING (-)-CIBENZOLINE SUCCINATE | December 2021 | July 2025 | Allow | 51 | 1 | 1 | No | No |
| 17621719 | METHOD FOR TREATING IDIOPATHIC PULMONARY FIBROSIS | December 2021 | November 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17616436 | BICYCLIC DERIVATIVES FOR TREATING ENDOPARASITES | December 2021 | March 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17615670 | 5,6-DIHETE LACTONE FOR TREATMENT OF MICROVASCULAR DYSFUNCTION | December 2021 | June 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17600535 | PREPARATION METHOD FOR LEVETIRACETAM INTERMEDIATE | September 2021 | October 2024 | Allow | 36 | 0 | 0 | No | No |
| 17434820 | TOTAL SYNTHESIS OF PIRFENIDONE | August 2021 | February 2025 | Allow | 42 | 1 | 0 | Yes | No |
| 17430794 | METHOD FOR PREPARING VORICONAZOLE AND INTERMEDIATE THEREOF | August 2021 | January 2025 | Allow | 41 | 1 | 0 | No | No |
| 17310380 | POLYMORPHIC FORMS OF A SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUND | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner FERGUSON, JALISA HOLMES works in Art Unit 1626 and has examined 8 patent applications in our dataset. With an allowance rate of 100.0%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.
Examiner FERGUSON, JALISA HOLMES's allowance rate of 100.0% places them in the 94% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by FERGUSON, JALISA HOLMES receive 0.88 office actions before reaching final disposition. This places the examiner in the 6% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by FERGUSON, JALISA HOLMES is 43 months. This places the examiner in the 15% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +0.0% benefit to allowance rate for applications examined by FERGUSON, JALISA HOLMES. This interview benefit is in the 12% percentile among all examiners. Note: Interviews show limited statistical benefit with this examiner compared to others, though they may still be valuable for clarifying issues.
When applicants file an RCE with this examiner, 50.0% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 0.0% of cases where such amendments are filed. This entry rate is in the 0% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 0.0% are granted (fully or in part). This grant rate is in the 0% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.